Halozyme Therapeutics (HALO) PT Raised to $66 at BMO Capital

August 10, 2021 9:04 AM

BMO Capital analyst Do Kim raised the price target on Halozyme Therapeutics (NASDAQ: HALO) to $66.00 (from $64.00) while maintaining ...

(Premium-only article. Please sign in or upgrade to SI Premium to view.)

No results found